menu
    • menu
    [{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Nephrology","graph2":"Phase III","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MBS303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MIL95","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MIL93","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MIL97","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MBS314","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Climb Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"CLYM116","moa":"APRIL","graph1":"Nephrology","graph2":"Preclinical","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Mabworks Biotech \/ Climb Bio","highestDevelopmentStatusID":"4","companyTruncated":"Beijing Mabworks Biotech \/ Climb Bio"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Mabworks Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Beijing Mabworks Biotech \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Beijing Mabworks Biotech

    Menu

    Beijing Mabworks Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIL62

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MIL62 Injection Tolerance, Safety, PK/PD, and Efficacy In Lupus Nephritis

                            Details : MIL62 is a drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 29, 2025

                            Lead Product(s) : MIL62

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLYM116

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Climb Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Climb Bio Expands Pipeline with Antibody Targeting APRIL Pathway in IgA Nephropathy

                            Details : Under the licensing agreement, Climb Bio will hold the exclusive rights to develop and commercialize MIL116 (CLYM116), an anti-APRIL monoclonal antibody, in the territory outside of Greater China.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $9.0 million

                            January 09, 2025

                            Lead Product(s) : CLYM116

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Climb Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBS314

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 30, 2024

                            Lead Product(s) : MBS314

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIL62

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase â…¢ Clinical Study of MIL62 in Primary Membranous Nephropathy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 17, 2023

                            Lead Product(s) : MIL62

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MBS303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 10, 2023

                            Lead Product(s) : MBS303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIL62

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study of MIL62 in Systemic Lupus Erythematosus

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 03, 2023

                            Lead Product(s) : MIL62

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIL62

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase Ib/ â…¡ Clinical Study of MIL62 in Primary Membranous Nephropathy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : MIL62

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIL62

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 06, 2022

                            Lead Product(s) : MIL62

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIL97

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Advanced and Metastatic Solid Tumors With MIL97

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 16, 2021

                            Lead Product(s) : MIL97

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed

                            Beijing Mabworks Biotech

                            China arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIL62

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphom...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 06, 2021

                            Lead Product(s) : MIL62

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth